ALG-2 is associated with cancer development [5,124], and clinical investigation of cancer cells and tissues have revealed the usefulness of monitoring the expression of ALG-2 (often quoted PDCD6) as a biomarker for prognosis [125,126,127]. Here, PDCD6 is linked to cancer.